HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells

Chemical Biology and Drug Design

Volumn 87, Issue 1, 2016, Pages 143-153

  Kozela, Ewa ^a   Haj, Christeene ^b   Hanuš, Lumir ^b   Chourasia, Mukesh ^c   Shurki, Avital ^b   Juknat, Ana ^a   Kaushansky, Nathali ^d   Mechoulam, Raphael ^b   Vogel, Zvi ^a,d  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c National Institute of Pharmaceutical Education and Research (NIPER)   (India)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

cannabidiol derivatives; encephalitogenic T cells; HU 446; HU 465; IL 17; Th17

Indexed keywords

CANNABIDIOL;

ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MASS SPECTROMETRY; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; T LYMPHOCYTE;

ANIMALS; CANNABIDIOL; DISEASE MODELS, ANIMAL; LYMPHOCYTE ACTIVATION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; T-LYMPHOCYTES;

EID: 84955680446     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12637     Document Type: Article

References (51)

1. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M., (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med Chem; 1: 1333-1349.
2. Tanasescu R., Constantinescu C.S., (2010) Cannabinoids and the immune system: an overview. Immunobiology; 215: 588-597.
3. Sospedra M., Martin R., (2005) Immunology of multiple sclerosis. Annu Rev Immunol; 23: 683-747.
4. Lyman W.D., Sonett J.R., Brosnan C.F., Elkin R., Bornstein M.B., (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol; 23: 73-81.
5. Maresz K., Pryce G., Ponomarev E.D., Marsicano G., Croxford J.L., Shriver L.P., Ledent C., et al,. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med; 13: 492-497.
6. Croxford J.L., Pryce G., Jackson S.J., Ledent C., Giovannoni G., Pertwee R.G., Yamamura T., Baker D., (2008) Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol; 193: 120-129.
7. Rimmerman N., Kozela E., Levy R., Vogel Z., Juknat A., (2013) Cannabinoid signaling through non-CB1, -non-CB2 GPCR targets in microglia. In:, Abood M.E., Sorensen R.G., Stella N., editors. Endocannabinoids: Actions at Non-CB1/CB2 Cannabinoid Receptors. New York: Springer; p 143-171.
8. Showalter V.M., Compton D.R., Martin B.R., Abood M.E., (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther; 278: 989-999.
9. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R., (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci; 30: 515-527.
10. Booz G.W., (2011) Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med; 51: 1054-1061.
11. Kozela E., Lev N., Kaushansky N., Eilam R., Rimmerman N., Levy R., Ben-Nun A., Juknat A., Vogel Z., (2011) Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol; 163: 1507-1519.
12. Mecha M., Feliú A., Iñigo P.M., Mestre L., Carrillo-Salinas F.J., Guaza C., (2013) Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis; 59: 141-150.
13. Duchi S., Ovadia H., Touitou E., (2013) Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol; 258: 32-40.
14. Rahimi A., Faizi M., Talebi F., Noorbakhsh F., Kahrizi F., Naderi N., (2015) Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience; 290: 279-287.
15. Pryce G., Riddall D.R., Selwood D.L., Giovannoni G., Baker D., (2015) Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J Neuroimmune Pharmacol; 10: 281-292.
16. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M., (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA; 97: 9561-9566.
17. Kozela E., Juknat A., Kaushansky N., Rimmerman N., Ben-Nun A., Vogel Z., (2013) Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol; 8: 1265-1276.
18. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Weaver C.T., (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol; 6: 1123-1132.
19. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med; 13: 1173-1175.
20. Siffrin V., Radbruch H., Glumm R., Niesner R., Paterka M., Herz J., Leuenberger T., Lehmann S.M., Luenstedt S., Rinnenthal J.L., Laube G., Luche H., Lehnardt S., Fehling H.J., Griesbeck O., Zipp F., (2010) In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity; 33: 424-436.
21. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y., (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol; 177: 566-573.
22. Mechoulam R., Shvo Y., Hashish I., (1963) The structure of cannabidiol. Tetrahedron; 19: 2073-2078.
23. Gaoni Y., Mechoulam R., (1971) The isolation and structure of Δ1-THC and other neutral cannabinoids from hashish. J Am Chem Soc; 93: 217-224.
24. Ben-Shabat S., Hanuš L.O., Katzavian G., Gallily R., (2006) New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem; 49: 1113-1117.
25. Bochevarov A.D., Harder E., Hughes T.F., Greenwood J.R., Braden D.A., Philipp D.M., Rinaldo D., Halls M.D., Zhang J., Friesner R.A., (2013) Jaguar: a high-performance quantum chemistry software program with strengths in life and materials sciences. Int J Quantum Chem; 113: 2110-2142.
26. Watts K.S., Dalal P., Murphy R.B., Sherman W., Friesner R.A., Shelley J.C., (2010) ConfGen: a conformational search method for efficient generation of bioactive conformers. J Chem Inf Model; 50: 534-546.
27. Fiser A., Do R.K., Sali A., (2000) Modeling of loops in protein structures. Protein Sci; 9: 1753-1773.
28. Lovell S.C., Davis I.W., Arendall W.B. III, de Bakker P.I., Word J.M., Prisant M.G., Richardson J.S., Richardson D.C., (2003) Structure validation by Cα geometry: phi, psi and Cβ deviation. Proteins; 50: 437-450.
29. Durdagi S., Papadopoulos M.G., Zoumpoulakis P.G., Koukoulitsa C., Mavromoustakos T., (2010) A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis. Mol Div; 14: 257-276.
30. Chen J.-Z., Wang J., Xie X.-Q., (2007) GPCR structure-based virtual screening approach for CB2 antagonist search. J Chem Inf Model; 47: 1626-1637.
31. Halgren T., (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model; 49: 377-389.
32. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S., (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem; 47: 1739-1749.
33. Poso A., Huffman J.W., (2008) Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br J Pharm; 153: 335-346.
34. Devane W.A., Breuer A., Sheskin T., Jarbe T.U.C., Eisen M., Mechoulam R., (1992) A novel probe for the cannabinoid receptor. J Med Chem; 35: 2065-2069.
35. Bayevitch M., Rhee M.H., Avidor-Reiss T., Breuer A., Mechoulam R., Vogel Z., (1996) (7)-Delta9-tetrahydro-cannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem; 271: 9902-9905.
36. Kaushansky N., Zhong M.C., Kerlero de Rosbo N., Hoeftberger R., Lassmann H., Ben-Nun A., (2006) Epitope specificity of autoreactive T and B cells associated with experimental autoimmune encephalomyelitis and optic neuritis induced by oligodendrocyte-specific protein in SJL/J mice. J Immunol; 177: 7364-7376.
37. Baek S.H., Srebnik M., Mechoulam R., (1985) Borontriuoride on alumina-a modified Lewis acid reagent. An improved synthesis of cannabidiol. Tetrahedron Lett; 26: 1083-1086.
38. 1-THC metabolites. J Chem Soc Perkin Trans; 1: 8-16.
39. Trachtenberg E.N., Carver J.R., (1970) Mechanism of selenium dioxide oxidation of olefins. J Org Chem; 35: 1653-1685.
40. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V., (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol; 134: 845-852.
41. Ai R., Chang C.A., (2012) Ligand-specific homology modeling of human cannabinoid (CB1) receptor. J Mol Graph Mod; 38: 155-164.
42. Pacher P., Mechoulam R., (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res; 50: 193-211.
43. Leleu-Chavain N., Desreumaux P., Chavatte P., Millet R., (2013) Therapeutical potential of CB2 receptors in immune-related diseases. Curr Mol Pharmacol; 6: 183-203.
44. Shevach E.M., (2011) Animal models for autoimmune and inflammatory diseases. In:, Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W., editors. Current Protocols in Immunology. New York: John Wiley & Sons; p. 15.0.1-15.0.5.
45. Yura M., Takahashi I., Serada M., Koshio T., Nakagami K., Yuki Y., Kiyono H., (2001) Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE). J Autoimmun; 17: 17-25.
46. Juknat A., Pietr M., Kozela E., Rimmerman N., Levy R., Gao F., Coppola G., Geschwind D., Vogel Z., (2013) Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS ONE; 8: e61462.
47. Kozela E., Pietr M., Juknat A., Rimmerman N., Levy R., Vogel Z., (2010) Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NFkappaB and interferon-β/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem; 285: 1616-1626.
48. Buckley N.E., (2008) The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol; 153: 309-318.
49. Hillard C.J., Pounds J.J., Boyer D.R., Bloom A.S., (1990) Studies of the role of membrane lipid order in the effects of delta 9-tetrahydrocannabinol on adenylate cyclase activation in heart. J Pharmacol Exp Ther; 252: 1075-1082.
50. Hanuš L.O., Tchilibon S., Ponde D.E., Breuer A., Fride E., Mechoulam R., (2005) Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem; 3: 1116-1123.
51. Fride E., Feigin C., Ponde D.E., Breuer A., Hanus L., Arshavsky N., Mechoulam R., (2004) (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol; 506: 179-188.